WallStreetZenWallStreetZen

NASDAQ: ELDN
Eledon Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for ELDN

Based on 1 analyst offering 12 month price targets for Eledon Pharmaceuticals Inc.
Min Forecast
$13.00+510.33%
Avg Forecast
$13.00+510.33%
Max Forecast
$13.00+510.33%

Should I buy or sell ELDN stock?

Based on 1 analyst offering ratings for Eledon Pharmaceuticals Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ELDN stock forecasts and price targets.

ELDN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-22

1 of 1

Forecast return on equity

Is ELDN forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
37.5%

Forecast return on assets

Is ELDN forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

ELDN revenue forecast

What is ELDN's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$17.4M
Avg 2 year Forecast
$109.0M
Avg 3 year Forecast
$193.0M

ELDN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ELDN$2.13$13.00+510.33%Buy
MLEC$1.38$6.00+334.78%Strong Buy
QTTB$16.17N/AN/A
UNCY$1.46$4.50+208.22%Buy
INAB$1.21$8.83+630.00%Strong Buy

Eledon Pharmaceuticals Stock Forecast FAQ

Is Eledon Pharmaceuticals Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ELDN) stock is to Buy ELDN stock.

Out of 1 analyst, 0 (0%) are recommending ELDN as a Strong Buy, 1 (100%) are recommending ELDN as a Buy, 0 (0%) are recommending ELDN as a Hold, 0 (0%) are recommending ELDN as a Sell, and 0 (0%) are recommending ELDN as a Strong Sell.

If you're new to stock investing, here's how to buy Eledon Pharmaceuticals stock.

What is ELDN's revenue growth forecast for 2028-2030?

(NASDAQ: ELDN) Eledon Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.

Eledon Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ELDN's revenue for 2028 to be $421,047,462, with the lowest ELDN revenue forecast at $421,047,462, and the highest ELDN revenue forecast at $421,047,462. On average, 1 Wall Street analysts forecast ELDN's revenue for 2029 to be $2,637,596,170, with the lowest ELDN revenue forecast at $2,637,596,170, and the highest ELDN revenue forecast at $2,637,596,170.

In 2030, ELDN is forecast to generate $4,670,239,090 in revenue, with the lowest revenue forecast at $4,670,239,090 and the highest revenue forecast at $4,670,239,090.

What is ELDN's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ELDN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is ELDN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ELDN price target, the average ELDN price target is $13.00, with the highest ELDN stock price forecast at $13.00 and the lowest ELDN stock price forecast at $13.00.

The Wall Street analyst predicted that Eledon Pharmaceuticals's share price could reach $13.00 by Mar 22, 2025. The average Eledon Pharmaceuticals stock price prediction forecasts a potential upside of 510.33% from the current ELDN share price of $2.13.

What is ELDN's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ELDN) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.